RPT 1G
Alternative Names: RPT-1GLatest Information Update: 10 Dec 2025
At a glance
- Originator Remedy Plan Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Preclinical Solid tumours
Most Recent Events
- 04 Dec 2025 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) (PO) prior to December 2025 (NCT07107126)
- 04 Dec 2025 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) (PO) prior to December 2025 (NCT07107126)
- 04 Dec 2025 Pharmacokinetics data from phase I trial in healthy volunteers released by Remedy Plan Therapeutics